Proteins and Peptides

13 June 2019

Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)

12 June 2019

OrthoTrophix Presents Clinical Data at European Congress of Rheumatology

12 June 2019

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

10 June 2019

Avacta Group plc Hits Clinical Candidate Selection Milestone for Affimer PD-L1 Inhibitor

10 June 2019

Lilly’s ultra rapid lispro provided similar A1C reductions compared to Humalog (insulin lispro), with superior post-meal blood glucose reductions

10 June 2019

Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments

9 June 2019

Lilly’s tirzepatide demonstrates benefits in data presented at the American Diabetes Association’s 79ᵗʰ Scientific Sessions

9 June 2019

Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

9 June 2019

Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

7 June 2019

La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis

7 June 2019

Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus

4 June 2019

Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy

3 June 2019

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

2 June 2019

Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting

2 June 2019

Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting

31 May 2019

Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO

30 May 2019

Merz Pharma: Xeomin® (incobotulinumtoxinA) Receives European Approval for Treatment of Chronic Sialorrhea in Adults

29 May 2019

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection

24 May 2019

Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication

23 May 2019

Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference

18 May 2019

U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)

14 May 2019

Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia

13 May 2019

TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee

13 May 2019

FDA Approves Broadened Indication for XEOMIN® (IncobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients

12 May 2019

NeuroVive’s IND for Clinical Development of NeuroSTAT Approved by FDA

7 May 2019

European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older

7 May 2019

Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China

30 April 2019

BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites

29 April 2019

Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

28 April 2019

Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Nectin-4-Targeted Immunotherapy Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

CD73 Inhibitor Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals